Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

THE REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) PATIENTS RECEIVING ABROCITINIB

NCT06353087 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06353087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06353087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
THE REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) PATIENTS RECEIVING ABROCITINIB
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 19, 2024
Completion date
June 22, 2026
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, dermatitis, atopic, eczema, immune system diseases, janus kinase inhibitors, skin diseases